MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company's national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. It has over 250 affiliated physicians who provide maternal-fetal care to expectant mothers experiencing complicated pregnancies and obstetrical hospitalist services in many areas where its affiliated neonatal physicians practice. Its physician specialties and services include neonatal care, anesthesia and anesthesia subspecialty care, pain management, maternal-fetal care, pediatric cardiology care, and other pediatric subspecialty care. It also offers revenue cycle management and consulting services.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialized Health Services
- Sub-Industry: Health Care Services
- Exchange: NYSE
- Symbol: MD
- CUSIP: 58502B10
- Previous Close: $70.73
- 50 Day Moving Average: $69.04
- 200 Day Moving Average: $66.17
- 52-Week Range: $59.36 - $76.96
- Trailing P/E Ratio: 20.14
- Foreward P/E Ratio: 15.08
- P/E Growth: 1.14
- Market Cap: $6.52B
- Outstanding Shares: 92,771,000
- Beta: 0.67
- Net Margins: 10.21%
- Return on Equity: 13.59%
- Return on Assets: 7.06%
Companies Related to Mednax:
- Debt-to-Equity Ratio: 0.73%
- Current Ratio: 1.44%
- Quick Ratio: 1.39%
What is Mednax's stock symbol?
Mednax trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
Where is Mednax's stock going? Where will Mednax's stock price be in 2017?
10 brokerages have issued 1 year target prices for Mednax's shares. Their predictions range from $63.00 to $80.00. On average, they anticipate Mednax's stock price to reach $70.88 in the next twelve months.
When will Mednax announce their earnings?
Mednax is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Mednax stock?
Here are some recent quotes from research analysts about Mednax stock:
According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (2/14/2017)
- Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)
Who owns Mednax stock?
Mednax's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (5.66%), State Street Corp (3.11%), William Blair Investment Management LLC (2.56%), Investec Asset Management LTD (1.27%), Thompson Siegel & Walmsley LLC (1.10%) and Flinton Capital Management LLC (0.90%). Company insiders that own Mednax stock include Cesar L Alvarez, Dominic J Andreano, John C Pepia, Joseph M Calabro, Karl B Wagner, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Roger Md Medel and Vivian Lopez-Blanco.
Who sold Mednax stock? Who is selling Mednax stock?
Mednax's stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, FMR LLC, Handelsbanken Fonder AB, Guggenheim Capital LLC, Allianz Asset Management AG, State Street Corp, Janus Capital Management LLC and Loomis Sayles & Co. L P. Company insiders that have sold Mednax stock in the last year include Dominic J Andreano, John C Pepia, Joseph M Calabro, Karl B Wagner, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos and Vivian Lopez-Blanco.
Who bought Mednax stock? Who is buying Mednax stock?
Mednax's stock was purchased by a variety of institutional investors in the last quarter, including Flinton Capital Management LLC, Tyers Asset Management LLC, Thompson Siegel & Walmsley LLC, New South Capital Management Inc., Arrowpoint Asset Management LLC, Asset Management One Co. Ltd., Russell Investments Group Ltd. and Frontier Capital Management Co. LLC.
How do I buy Mednax stock?
Shares of Mednax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Mednax stock cost?
One share of Mednax stock can currently be purchased for approximately $70.28.